07:00 , Jun 23, 2016 |  BC Innovations  |  Tools & Techniques

Home is in the placenta

Many drug developers have avoided stepping into what they see as the high risk area of pregnancy-associated complications, leaving diseases such as preeclampsia and fetal growth restriction with little innovation and few treatment options. By...
07:00 , Apr 21, 2016 |  BC Innovations  |  Product R&D

A1M for preeclampsia

A poor understanding of disease biology and a challenging development pathway have kept most drug developers away from the serious pregnancy complication preeclampsia, but A1M Pharma AB has a new approach with a first-in-class therapy...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Alnylam pharmaceuticals news

Alnylam outlined plans to focus its RNAi pipeline on genetic medicine, cardio-metabolic diseases and hepatic infectious diseases. Clinical genetic medicine programs include Phase III transthyretin-mediated amyloidosis (ATTR) candidates patisiran and revusiran as well as Phase...
07:00 , Oct 16, 2014 |  BC Innovations  |  Targets & Mechanisms

Alnylam interrupts preeclampsia

Preeclampsia often involves overactivation of the renin-angiotensin system that regulates blood pressure, but inhibiting the pathway is not possible because it would be toxic to the fetus. Alnylam Pharmaceuticals Inc. has developed an siRNA conjugate...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Alnylam preclinical data

In a rat model of preeclampsia, subcutaneous ALN-AGT led to >90% knockdown of maternal angiotensinogen (AGT) in the liver with no detectable evidence of fetal drug exposure. ALN-AGT also significantly reduced mean arterial blood pressure...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Angiotensinogen (AGT); angiotensin-converting enzyme (ACE) Patient tissue and mouse studies suggest ACE inhibitors could help treat NSCLC in patients with...
08:00 , Feb 8, 2010 |  BioCentury  |  Strategy

Out from Down Under

A dearth of funding often forces Australian companies to out-license products too early in development to get any meaningful revenues out of them, because they can't afford to get them to market by themselves. By...
08:00 , Jan 8, 2007 |  BioCentury  |  Strategy

Thinking globally

Thinking globally...
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

Cloretazine: Phase II started

VION started a Phase II trial in up to 90 patients. Cloretazine, which has Fast Track and Orphan Drug designations for acute myelogenous leukemia (AML), is in the clinic for various cancers. Vion Pharmaceuticals Inc....